Article Text

Download PDFPDF
Lansoprazole for children with poorly controlled asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Design: Randomised placebo-controlled trial (RCT).

Allocation: 1:1 ratio of intervention:placebo using permuted-block assignment stratified by clinical centre.

Setting: 19 American Lung Association Asthma Clinical Research Center sites from April 2007 to April 2011.

Patients: Children aged 6–17 years (mean 11 years) with physician and lung function confirmed poorly controlled asthma, all of whom had been treated with inhaled corticosteroids for at least 8 weeks prior to enrolment. Patients with current or previous gastro-oesophageal reflux disease requiring treatment were excluded. A subgroup of 115 received pH studies.

Intervention: 149 children received lansoprazole (15 mg/day <30 kg or 30 mg/day >30 kg) and 157 received placebo.

Outcomes: Primary outcome—Change in Asthma Control Questionnaire (ACQ) score. Secondary outcomesRate of episodes of acute asthma, asthma symptom utility index, asthma control test for adolescents, asthma-specific quality of life for children score, meaningful clinically important changes in lung function tests, gastrointestinal symptoms or nocturnal awakenings.

Follow-up period: …

Correspondence to Dr Cara Bossley, Department of Paediatrics, King's College Hospital, London, UK; cara.bossley{at}

View Full Text


  • Provenance and peer review Commissioned; internally peer reviewed.